Objective: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ritonavir and cobicistat. Considerations when switching from one booster to another are discussed. Data Sources: A literature search of MEDLINE was performed (1985 to April 2017) using the following search terms: cobicistat, ritonavir, pharmacokinetic, drug interactions, booster, pharmacokinetic enhancer, HIV, antiretrovirals. Abstracts from conferences, article bibliographies, and product monographs were reviewed. Study Selection and Data Extraction: Relevant Englishlanguage studies or those conducted in humans were considered. Data Synthesis: Similar exposures of elvitegravir, darunavir, and atazanavir are achieved when combined with cobicistat or ritonavir. Cobicistat may not be as potent a CYP3A4 inhibitor as ritonavir in the presence of a concomitant inducer. Ritonavir induces CYP1A2, 2B6, 2C9, 2C19, and uridine 5′-diphospho-glucuronosyltransferase, whereas cobicistat does not. Therefore, recommendations for cobicistat with comedications that are extrapolated from studies using ritonavir may not be valid. Pharmacokinetic properties of the boosted antiretroviral can also affect interaction outcome with comedications. Problems can arise when switching patients from ritonavir to cobicistat regimens, particularly with medications that have a narrow therapeutic index such as warfarin. Conclusions: When assessing and managing potential interactions with ritonavir-or cobicistat-based regimens, clinicians need to be aware of important differences and distinctions between these agents. This is especially important for patients with multiple comorbidities and concomitant medications. Additional monitoring or medication dose adjustments may be needed when switching from one booster to another.
Introduction
Sustained viral load suppression is a key goal of antiretroviral therapy and is related to adequate drug exposure. 1 Pharmacokinetic enhancing strategies utilize either a low dose of the protease inhibitor (PI) ritonavir or the pharmacokinetic enhancer cobicistat. Both drugs are potent inhibitors of the CYP3A4 isoenzyme and achieve the desired goal of boosting plasma drug concentrations and prolonging half-life of the CYP3A substrate (ie, atazanavir, darunavir, or elvitegravir) they are paired with.
Ritonavir, initially launched as a PI in 1996 at 600 mg twice daily for use with other antiretrovirals for treatment of HIV 2 was plagued by high pill burden, poor tolerability, need for dose escalation, and drug interactions. Use of ritonavir then evolved to that of a pharmacokinetic enhancer.
At doses of 100 mg once or twice daily, ritonavir was better tolerated and effective in enhancing the pharmacokinetic profile of partner PIs through inhibition of intestinal and hepatic CYP3A4 and P-glycoprotein (P-gp), resulting in increases in the area under the curve (AUC), maximum concentration (C max ), and half-life. 3 This allowed less-frequent dosing, lower pill burden, reduced impact of food on bioavailability, reduced variability of systemic drug exposure, and improved treatment efficacy. 4 Cobicistat was approved as a pharmacokinetic enhancing agent in 2012 to address limitations of ritonavir such as coformulation difficulties secondary to poor water solubility and drug interactions secondary to its broad effects on CYP isoenzymes and drug transporters. Cobicistat is generally considered to be an equipotent inhibitor of CYP3A4 and P-gp as ritonavir and is coformulated with the PIs darunavir and atazanavir and the integrase inhibitor elvitegravir. However, there are important pharmacokinetic distinctions between cobicistat and ritonavir, which may lead to clinically significant differences in drug interaction outcomes. This review aims to compare and contrast the pharmacological characteristics, pharmacokinetic boosting data, and drug interaction studies for ritonavir and cobicistat, with an emphasis on relevance to clinical practice. A discussion on considerations when switching from one booster to another is included to guide clinicians.
Data Sources
We performed a search of the MEDLINE database (1985 to April 2017) using the following search terms: cobicistat, ritonavir, drug interactions, pharmacokinetic, booster, pharmacokinetic enhancer, HIV, and antiretrovirals. Conference abstracts, reference lists of relevant articles, and product monographs were also reviewed. Search results were limited to studies conducted in humans and published in the English language.
Pharmacokinetics/Pharmacodynamics
Ritonavir Ritonavir is a potent inhibitor of the CYP3A4 isoenzyme and also inhibits CYP2D6, CYP2C19, CYP2C8, and CYP2C9. [3] [4] [5] In addition, ritonavir inhibits P-gp and the cellular transport mechanism via this efflux pump. Inhibition of P-gp may contribute to the drug boosting effects through disruption of the active transport of PIs out of cells from the intestinal tract, liver, and kidneys. Furthermore, ritonavir is a known inducer of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and the uridine 5′-diphospho-glucuronosyltransferase (UGT) family. 6 Other drug transporters inhibited by ritonavir include the breast cancer resistance protein (BCRP), the organic anion transporting polypeptides (OATPs) located in the liver, and multiantimicrobial extrusion protein 1 (MATE1). 7 The major metabolite of ritonavir is isopropylthiazole, which displays antiviral activity similar to that of the parent compound. Ritonavir undergoes extensive hepatic metabolism primarily through CYP3A4 and to a lesser degree CYP2D6. The majority of elimination is in the faeces, with the remaining in the urine. The elimination half-life of the parent compound is between 3 and 5 hours. No dosage adjustments are required for ritonavir in patients with renal failure or mild (Child-Pugh class A) or moderate (Child-Pugh class B) hepatic impairment. 2 
Cobicistat
Cobicistat is a structural analogue of ritonavir without antiviral activity. It has improved physiochemical properties compared with ritonavir and is a potent inhibitor of CYP3A and a weak inhibitor of CYP2D6. Cobicistat inhibits the transporters P-gp, BCRP, OATP1B1, and OATP1B3. 8 Cobicistat 150 mg once daily has a pharmacokinetic boosting effect comparable with that of ritonavir 100 mg once daily. 9 In contrast to ritonavir, cobicistat does not demonstrate any enzyme-inducing effects on CYP450, UGT, or P-gp. 8 There is reduced activation of the pregnane X receptor, which regulates expression of different drug-metabolizing enzymes and demonstrates the reduced impact of cobicistat on concomitant medications. 10 Cobicistat inhibits renal cation transporters, including OATPs and MATE1. MATE1 is involved in the renal tubular secretion of creatinine, and studies involving cobicistat and ritonavir have identified 10% to 15% increases in serum creatinine concentrations, with no impairment of actual renal function. 11 The rise of serum creatinine with cobicistat is more pronounced compared with ritonavir, which may be explained by active transport of cobicistat in the tubular cells by organic cation transporter (OCT2), leading to accumulation of cobicistat and greater inhibition of MATE1. 10 In a randomized study comparing atazanavir boosted with cobicistat versus ritonavir in combination with emtricitabine/tenofovir disoproxil fumarate (TDF) in treatmentnaïve patients, median increases in serum creatinine were higher in the cobicistat arm compared with the ritonavir arm (0.13 vs 0.09 mg/dL, respectively; P < 0.001); these changes were observed as early as week 2 and remained stable after week 8. 12 Metabolism of cobicistat is predominantly by CYP3A4 and to a lesser degree CYP2D6. However, overall metabolism in the body is minimal because 99% is excreted unchanged (90% faeces, 10% urine), and the metabolites formed exhibit negligible clinical activity. No dosage adjustments are necessary for patients with renal failure or mild to moderate hepatic impairment. There are no data available relating to dosage adjustments in severe hepatic impairment. 8
Pharmacokinetic Boosting (Atazanavir, Darunavir, Elvitegravir, Tipranavir)
The pharmacokinetic effects of cobicistat versus ritonavir on the properties of atazanavir, darunavir, elvitegravir, and tipranavir are summarized in Table 1 . For atazanavir, bioequivalent exposures in volunteers 13 were further supported by a phase II study conducted in HIV-1 infected treatmentnaïve participants, where cobicistat 150 mg and ritonavir 100 mg were found to be bioequivalent based on AUC τ , C max , and C τ . 14 A phase I, multiple-dose, crossover study found that cobicistat 150 mg provided equivalent darunavir C max and AUC τ , but bioequivalence was not established for darunavir C τ compared with ritonavir 100 mg. 15 Similarly, a randomized, 3-way crossover trial evaluated the oral bioavailability of darunavir 800 mg/ritonavir 100 mg daily and 2 fixeddose combinations (FDCs) of darunavir 800 mg/cobicistat 150 mg daily in healthy volunteers; darunavir AUC 24h was comparable with both boosters, whereas a slightly lower darunavir C min was seen with the cobicistat FDCs versus ritonavir. 16 These differences are not considered to be clinically significant in treatment-naïve patients.
Cobicistat and ritonavir equally effectively boost elvitegravir. 15 A study evaluating the bioavailability and pharmacokinetics of a FDC tablet (elvitegravir/cobicistat/ emtricitabine/TDF) showed bioequivalent exposures for elvitegravir AUC τ and C max , but a lower C τ compared with elvitegravir/ritonavir. 17 In contrast, cobicistat is not an adequate booster for the PI tipranavir. In a fixed-sequence crossover study, the pharmacokinetics of tipranavir 500 mg twice daily with either cobicistat 150 mg twice daily or ritonavir 200 mg twice daily were assessed. When combined with cobicistat, tipranavir concentrations were significantly lower compared with those achieved with ritonavir. 18 It is interesting to speculate whether a higher dose of cobicistat (ie, 300 mg twice daily) would have been more successful, given that for tipranavir, the effective boosting dose of ritonavir is double the usual twice-daily boosting dose for other PIs.
Cobicistat Interactions With Other Antiretrovirals
Cobicistat has been investigated as a booster for 2 antiretrovirals simultaneously. Interactions between cobicistatboosted agents and other antiretrovirals may need to be considered when managing treatment-experienced patients who require nontraditional antiretroviral combinations. Drug interaction studies involving cobicistat-boosted elvitegravir or darunavir plus other antiretrovirals are described below. Drug interaction studies involving atazanavir/cobicistat with other antiretrovirals have not been conducted. 
Nonnucleoside Reverse Transcriptase Inhibitors With Cobicistat-Boosted Elvitegravir or Darunavir
(a) Efavirenz plus elvitegravir/cobicistat. In a 3-period study, healthy individuals received elvitegravir/cobicistat/emtricitabine/TDF on days 1 to 7 followed by a washout, efavirenz/emtricitabine/TDF on days 15 to 28 and elvitegravir/cobicistat/emtricitabine/ TDF on days 29 to 62. At day 35, elvitegravir AUC, C max , and C τ were reduced by 37%, 19%, and 67%, respectively, compared with day 7. Mean elvitegravir C trough values were 3-fold and 5-fold higher than protein-adjusted IC95 of wild-type virus on days 35 and 42, respectively, and 7-to 8-fold higher at 5 weeks postswitch. Cobicistat C τ was reduced 35% at day 14 postswitch compared with day 7, and cobicistat AUC returned to normal by day 42. Over the duration of the 5-week period postswitch, all patients had efavirenz C trough above IC90. These results indicate that patients on efavirenz-containing regimens may be switched immediately to a elvitegravir/cobicistat regimen without dose adjustment because efavirenz concentrations remain therapeutic during the initial period of lower elvitegravir exposures. However, long-term coadministration of efavirenz and elvitegravir/cobicistat should be avoided because elvitegravir concentrations will be subtherapeutic. 18 (b) Etravirine plus elvitegravir/ritonavir. In healthy individuals, no clinically relevant pharmacokinetic changes were observed when elvitegravir 150 mg/ritonavir 100 mg daily and etravirine 200 mg twice daily were coadministered. 19 There are no data regarding etravirine with cobicistat-boosted elvitegravir. (c) Etravirine plus darunavir/cobicistat. In a study assessing the pharmacokinetics of darunavir 600 mg/ cobicistat 150 mg twice daily alone or with etravirine 200 mg twice daily, darunavir exposures were not significantly affected by coadministration with etravirine, and etravirine exposures were comparable to historical data. 20 However, darunavir/cobicistat is only available as an 800-mg/150-mg coformulation approved for once-daily dosing. Although a phase II single-arm study in HIV-infected individuals of darunavir 800 mg/ritonavir 100 mg daily plus etravirine 400 mg daily showed no significant changes in either darunavir or etravirine with coadministration, 21 an open-label, fixed sequence study in 30 HIV-infected subjects showed marked reductions in cobicistat (30% reduction AUC, 66% reduction in C24h) and 56% reduction in darunavir C24h with coadministration of darunavir 800 mg/cobicistat 150 mg and etravirine 400 mg daily compared to darunavir/cobicistat administered alone. 22 . The darunavir/cobicistat monograph states that coadministration of etravirine is not recommended. 23 If therapy with both etravirine and darunavir is required, ritonavir may be the preferred booster.
Elvitegravir Plus a PI Using Cobicistat as a Dual Antiretroviral Booster
(a) Atazanavir plus elvitegravir/cobicistat. A study in healthy individuals compared elvitegravir 85 mg/ cobicistat 150 mg plus atazanavir 300 mg daily to either elvitegravir 150 mg/cobicistat 150 mg daily or atazanavir 300 mg/ritonavir 100 mg daily. Elvitegravir C τ increased more than 80% when dosed with atazanavir/cobicistat. All atazanavir, elvitegravir, and cobicistat pharmacokinetics were comparable with reference or historical data. 24 However, elvitegravir is not available as an 85-mg dose with cobicistat. (b) Darunavir plus elvitegravir/cobicistat. Cobicistat appears to be an effective dual booster of darunavir and elvitegravir when administered twice daily. In a study assessing the kinetics of darunavir 600 mg/ cobicistat 150 mg twice daily plus elvitegravir 150 mg daily compared with darunavir 600 mg/cobicistat 150 mg twice daily alone, darunavir exposures were not significantly affected by coadministration with elvitegravir, and elvitegravir exposures were comparable to historical reference data. 20 However, observations with once-daily dosing are conflicting. When darunavir 800 mg was administered with elvitegravir 150 mg/cobicistat 150 mg once daily in healthy volunteers, elvitegravir C trough was approximately 50% lower compared with exposures achieved with elvitegravir/cobicistat/TDF/emtricitabine without darunavir, and darunavir C trough was 20% lower compared with darunavir 800 mg administered with cobicistat 150 mg daily alone. 20 In a retrospective case series of HIV-infected, treatment-experienced individuals receiving darunavir 800 mg plus elvitegravir/cobicistat/TDF/emtricitabine once daily, median darunavir C trough values were 80% lower compared with historical population data. Elvitegravir concentrations were not measured in this study. All patients reported 100% adherence, and only 1 patient had a darunavir resistance-association mutation. Detectable minor increases in HIV viral load were observed in 3 patients. 25 In contrast, in a pharmacokinetic substudy of a simplification trial involving darunavir 800 mg plus elvitegravir/cobicistat/TAF/emtricitabine in treatment-experienced, HIV-infected individuals, both darunavir and elvitegravir exposures were similar to historical controls. 26 The reasons for these varying results are unclear but may be related to significant interpatient variability or differences in pharmacokinetics between HIV-infected individuals and healthy controls.
Drug Interaction Studies (Nonantiretrovirals): Cobicistat Versus Ritonavir
There are limited drug interaction studies evaluating cobicistat, and concomitant medications and drug interactions are often inferred based on the pharmacokinetic properties of cobicistat. For instance, drug interaction studies were initially not conducted with atazanavir/cobicistat, and recommendations from the product monograph include predicted interactions as well as results of drug interaction studies of unboosted atazanavir, atazanavir/ritonavir, and cobicistat alone or as a booster for another agent. 27 Similarly, drug interaction information in the elvitegravir/cobicistat/TDF/ emtricitabine monograph includes studies involving the coformulated product or elvitegravir with either cobicistat or ritonavir (as well as any pertinent interactions for emtricitabine or TDF). Although this approach is generally appropriate, differences between the effects of cobicistat versus ritonavir on certain metabolizing enzymes and transporters may result in different and sometimes opposite effects on the disposition of coadministered medications. It is notable that the darunavir/cobicistat monograph states that the interaction profile of darunavir is dependent on which pharmacokinetic booster is used and highlights instances when drug interaction recommendations for darunavir/cobicistat are different from those for darunavir/ritonavir. Examples of similarities and differences between ritonavir-versus cobicistat-boosted agents are described below and summarized in Tables 2 to 4 .
Gastric Acid-Reducing Agents
The pharmacokinetics of elvitegravir boosted with either cobicistat or ritonavir are not affected by acid-reducing agents such as H2-blockers or proton pump inhibitors. 28 In healthy individuals receiving darunavir 400 mg/ritonavir 100 mg twice daily, administration of ranitidine 150 mg twice daily or omeprazole 20 mg daily did not alter darunavir or ritonavir AUC. 29 It is important to also consider which antiretroviral is being boosted by ritonavir or cobicistat. In contrast to elvitegravir and darunavir, atazanavir absorption is dependent on gastric pH. With respect to coadministration of H2-receptor antagonists, recommendations for atazanavir boosted with either cobicistat or ritonavir are similar for treatment-naïve patients or in treatment-experienced patients not receiving concomitant TDF. Boosted atazanavir should be administered simultaneously with or at least 10 hours after a dose of the H2-receptor antagonist. However, the recommendations in treatment-experienced patients who are also taking TDF vary according to the booster used. In this situation, a dose of atazanavir 400 mg with ritonavir 100 mg is recommended 30 ; because atazanavir/cobicistat is a fixed-dose coformulated product, such a dose adjustment is not possible, and use of atazanavir/cobicistat is not recommended. 27 Of note, unlike TDF, pharmacokinetic data suggest that TAF does not significantly affect the pharmacokinetics of atazanavir/ritonavir, and standard boosted atazanavir doses may be used. 31 
CYP3A4 Substrates
Dose finding studies confirmed potent CYP3A4 inhibitory effects of cobicistat at doses of 100 to 200 mg as evidenced by a 95% reduction in midazolam clearance. This was comparable to a 96% reduction in midazolam clearance seen with ritonavir 100 mg once daily. 32 A number of case reports highlight the potential for serious interactions with cobicistat via CYP3A4 inhibition. An HIV-infected man developed iatrogenic Cushing's syndrome as a result of an interaction between elvitegravir/cobicistat and fluticasone nasal drops. 33 A patient undergoing treatment for Hodgkin's lymphoma developed severe peripheral neuropathy, thought to be secondary to an interaction between elvitegravir/cobicistat and vinblastine. 34 Several cases of significantly elevated tacrolimus concentrations and toxicity have been reported in HIV-infected renal transplant patients following coadministration of elvitegravir/cobicistat and tacrolimus. [35] [36] [37] Extensive bruising and elevated rivaroxaban concentrations were observed in a patient on elvitegravir/ cobicistat, 38 and severe acute leg ischemia occurred following ingestion of an ergotamine-containing preparation by a patient on elvitegravir/cobicistat. 39 Of note, whereas ergot alkaloids, fluticasone, and tacrolimus are mentioned in the product monographs for elvitegravir/cobicistat, vinblastine and rivaroxaban are not. These reports reinforce the importance of avoiding cobicistat or ritonavir with drugs that have narrow therapeutic indices or close monitoring with dose adjustment of therapy if coadministration is required.
Coadministration With CYP3A4 Inducers
An open-label fixed sequence study of elvitegravir 150 mg/ cobicistat 150 mg daily and carbamazepine 100 mg twice daily for 3 days followed by 200 mg twice daily up until day 41 in 14 healthy individuals demonstrated a 43% increase in the AUC of carbamazepine and a 69% and 97% decrease in elvitegravir AUC and C τ , respectively. 40 Carbamazepine is contraindicated with elvitegravir, 28 atazanavir/cobicistat, 27 and darunavir/cobicistat, and an alternative anticonvulsant should be used if possible. 41 With ritonavir-boosted PIs, recommendations on coadministration are different. The atazanavir/ritonavir product monograph states that carbamazepine concentrations may be increased and atazanavir concentrations may be decreased. Therapeutic drug monitoring of both agents may be helpful, with close monitoring and dose adjustments as necessary. 30 For darunavir/ritonavir, the manufacturer suggests monitoring for carbamazepine efficacy/toxicity; a 25% to 50% reduction in carbamazepine dose may be necessary, whereas dosage adjustment for darunavir/ritonavir is likely not required. 41 However, clinicians should be aware that these recommendations are based on results of an interaction study in healthy volunteers where coadministration of darunavir 600 mg/ritonavir 100 mg twice daily plus carbamazepine 200 mg twice daily resulted in a 14% reduction in darunavir C min with no change in AUC, a 54% increase in C min and 45% increase in AUC of carbamazepine, and 52% reduction in C min and 54% reduction in the AUC of carbamazepine-epoxide compared with either drug administered alone. It is unclear whether darunavir exposures would be similarly unaffected if administered at a once-daily dose in the presence of carbamazepine. Therefore, close monitoring is recommended if coadministration is required. Rifabutin, an antimycobacterial agent, is also an inducer of CYP3A4. The metabolism of rifabutin involves first-pass metabolism by CYP3A4 in the intestine and CYP3A4 metabolism in the liver of the active metabolite 25-desacetyl metabolite. 42 Initially, rifabutin was studied with ritonavir-boosted elvitegravir. Healthy individuals received elvitegravir 300 mg/ritonavir 100 mg daily alone and with rifabutin 150 mg every other day versus rifabutin 300 mg daily. 43 The pharmacokinetics of elvitegravir, ritonavir, and rifabutin were within the no-effect boundary, although AUC of 25-desacetyl metabolite increased by 951%. In contrast, in a pharmacokinetic study of healthy volunteers, coadministration of rifabutin 150 mg every other day and elvitegravir 150 mg/cobicistat 150 mg daily resulted in a 67% decrease in elvitegravir C τ compared with elvitegravir/ cobicistat administered alone, and 625% increase in AUC of 25-desacetyl metabolite. 24 A subsequent pharmacokinetic study demonstrated that increasing cobicistat to 150 mg twice daily mitigated the effect of rifabutin on elvitegravir concentrations. 44 However, the practicality of this strategy is limited given that cobicistat is not licensed for more than once-daily dosing, and cobicistat as a sole agent may not be readily available. Therefore, if rifabutin use is required, an alternative antiretroviral regimen should be considered.
Recently, an in vitro study demonstrated that ritonavir was more potent than cobicistat in overcoming rifampininduced increase in darunavir clearance. 45 These findings, along with the etravirine, tipranavir, carbamazepine, and rifabutin interaction studies suggest that cobicistat may not be as effective as ritonavir in overcoming CYP3A4 induction in the presence of concomitant inducers. Therefore, coadministration of cobicistat-regimens with moderatepotent enzyme inducers should be avoided.
Other CYP450 Enzymes and Drug Transporters
At boosting doses, cobicistat and ritonavir are weak CYP2D6 inhibitors. In healthy volunteers, cobicistat 150 mg daily increased desipramine AUC 58% to 65%, 46 whereas desipramine AUC was increased 26% with ritonavir 100 mg twice daily 47 and increased 145% with ritonavir 500 mg twice daily. 2 This example serves as a reminder to be cognizant of the ritonavir dose used in drug interaction studies because CYP-mediated inhibition is often dose related, and effects observed with high-dose ritonavir may not occur at the same magnitude at lower doses. 48 One of the principal differences between cobicistat and ritonavir is the impact on other CYP isoenzymes. As previously stated, ritonavir induces CYP1A2, CYP2B6, CYP2C9, CYP2C19, and UGT, 6 whereas cobicistat is not known to induce these enzymes. A study in healthy volunteers taking the CYP2B6 substrate sertraline 50 mg and elvitegravir/cobicistat/TAF/emtricitabine found no clinically relevant changes in sertraline pharmacokinetics. 49 In contrast, sertraline AUC was decreased 49% when coadministered with darunavir 400 mg/ritonavir 100 mg twice daily, suggesting a potent CYP2B6 induction effect of ritonavir. 41 Ritonavir 100 mg twice daily has been shown to reduce exposures of bupropion, another CYP2B6 substrate by 21% and 57% when given either alone or with lopinavir 400 mg twice daily, respectively. [50] [51] The product monographs for ritonavirboosted darunavir, 41 lopinavir/ritonavir, 48 and ritonavir 2 state that bupropion exposures may be decreased and dose titration may be required. In contrast, product monographs for cobicistat-boosted darunavir 23 or elvitegravir 28 mention the possibility of increased sertraline or bupropion concentrations.
Methadone undergoes oxidative metabolism in the liver by CYP2B6, CYP3A4, CYP2C19, CYP2D6, and CYP2C8. R-methadone and S-methadone concentrations were not significantly affected by elvitegravir/cobicistat, and symptoms of opioid withdrawal or toxicity were not observed. 52 Ritonavir-boosted PIs, on the other hand, have been shown to decrease R-and S-methadone concentrations, and monitoring for withdrawal symptoms and need for dose adjustment is recommended. [53] [54] Warfarin is also a mixture of 2 enantiomers: the S-enantiomer is more potent and is primarily metabolized by CYP2C9, and the R-enantiomer is metabolized primarily via CYP1A2, CYP3A4, and CYP2C19. 55 Ritonavir-boosted PIs have been shown to decrease warfarin concentrations via CYP2C9 induction. 56 This interaction would not be expected when cobicistat is administered with darunavir or atazanavir. This is illustrated in a case report of an HIV-positive individual stabilized on warfarin 10 mg daily and atazanavir/ ritonavir-based therapy. When atazanavir/ritonavir was replaced with darunavir/cobicistat, the patient experienced increased international normalized ratio (INR) and bleeding, and a 60% reduction in warfarin dose was required. 57 Of note, elvitegravir modestly induces CYP2C9 28 ; a 60% increase in warfarin dose was required to maintain therapeutic INR after therapy with elvitegravir/cobicistat/emtricitabine/TDF was initiated. 55 Therefore, pharmacological properties of both the specific pharmacokinetic enhancer as well as the coadministered boosted antiretroviral need to be considered when considering potential drug interactions with warfarin.
Buprenorphine is metabolized to its active metabolite, nor-buprenorphine, via CYP3A4, CYP 3A5, CYP3A7, and CYP2C8; nor-buprenorphine is further metabolized via CYP3A4, and both the parent and metabolite undergo subsequent glucuronidation. 58 In HIV-seronegative individuals stabilized on buprenorphine/naloxone, elvitegravir 150 mg/ cobicistat 150 mg daily increased buprenorphine and nor-buprenorphine AUC τ by 35% and 42%, respectively, and decreased naloxone AUC τ by 28%. These changes did not result in opioid toxicity or withdrawal symptoms, and these agents may be coadministered without dosage adjustments. 58 Similarly, there was no change in buprenorphine exposures and a 46% increase in AUC of norbuprenorphine when coadministered with darunavir 600 mg/ritonavir 100 mg twice daily. 41 In contrast, atazanavir inhibits UGT1A1 in addition to CYP3A4; thus, slightly larger increases in buprenorphine and norbuprenorphine exposures are observed in the presence of atazanavir or atazanavir/ritonavir. With atazanavir 300 mg/ritonavir 100 mg, AUC of buprenorphine and norbuprenorphine increased by 67% and 105%, respectively, and increased by 93% and 76%, respectively, when coadministered with atazanavir 400 mg once daily. 30 A priori dose adjustments of buprenorphine are not required with either elvitegravir/cobicistat 28 or darunavir boosted with either cobicistat 23 or ritonavir. 41 In contrast, when coadministered with atazanavir alone or with a booster, monitoring for increased buprenorphine effects is recommended, and dose adjustment may be necessary. 30 Ethinyl estradiol is extensively metabolized by CYP3A4, CYP2C9, and UGT, in particular UGT1A1. 59 Recommendations on coadministration with boosted antiretrovirals vary according to the booster used as well as the antiretroviral it is combined with. Ethinyl estradiol exposures are decreased 19% in the presence of atazanavir/ritonavir, presumably secondary to UGT induction by ritonavir, 60 and the manufacturer recommends use of an oral contraceptive with a minimum 30 µg ethinyl estradiol content. However, when coadministered with unboosted atazanavir, ethinyl estradiol concentrations are increased 48% because of UGT1A1 inhibition by atazanavir, 61 and in this case, an oral contraceptive with no more than 30 µg ethinyl estradiol is recommended. 30 With atazanavir/cobicistat, the manufacturer suggests consideration of nonhormonal contraception based on the unboosted atazanavir-hormonal contraceptive interaction data. 27 In contrast, ethinyl estradiol AUC and C min were reduced 25% and 44%, respectively, when administered with elvitegravir/cobicistat/TDF/emtricitabine. 62 These results may reflect CYP2C9 induction by elvitegravir; therefore, oral contraceptives with at least 30 µg of ethinyl estradiol should be used in combination with elvitegravir/cobicistat/TDF/emtricitabine.
The prodrug dabigatran etexilate (DE) is converted to dabigatran by esterase-catalyzed hydrolysis in plasma and the liver. DE is a substrate of P-gp; thus, concomitant use of potent P-gp inducers or inhibitors may affect exposures of DE and affect the amount of DE available for conversion to dabigatran. A healthy volunteer study assessed DE in the presence of cobicistat 150 mg daily. With simultaneous administration, dabigatran AUC increased by 127%, thrombin time at 24 hours (TTlast) increased by 46% to 51%, and AUC for TT increased by 30% to 33%. Spacing administration of cobicistat and DE by 2 hours did not mitigate the interaction. In contrast, no significant effect was observed on dabigatran exposures when ritonavir 100 mg was administered simultaneously. 63 Case reports showed no interaction when dabigatran 110 or 150 mg twice daily was administered to patients on lopinavir/ritonavir 64 and atazanavir/ritonavir, 65 respectively, with dabigatran C trough similar to those observed in the RE-LY trial. 66 Interestingly, although these data appear to suggest a greater effect of cobicistat on dabigatran exposures compared with ritonavir, dabigatran is not mentioned in the elvitegravir/cobicistat or atazanavir/cobicistat monographs. For both ritonavir-and cobicistat-boosted darunavir, the manufacturer recommends use of this combination with caution and avoidance in individuals with severe renal impairment. Similar precautions should also be considered when using dabigatran with elvitegravir/cobicistat or atazanavir/cobicistat.
Rosuvastatin is a substrate for BCRP, OATP1B1, OATP1B3, and OAT3, with CYP2C9 being a minor pathway of disposition. 67 In healthy individuals, elvitegravir/ cobicistat increased rosuvastatin C max by 89% and AUC inf by 38%; however, these drugs may be coadministered without dose adjustment. 68 In contrast, mean rosuvastatin AUC increased by 48%, and 93% and C max increased by 144% and 277% in the presence of darunavir 600 mg/ritonavir 100 mg twice daily 69 and darunavir 800 mg/cobicstat 150 mg daily, respectively. 70 Similarly, rosuvastatin AUC increased by 213% and 242% and Cmax increased 600% and 958%, when coadministered with atazanavir 300 mg/ ritonavir 100 mg daily 71 or atazanavir 300 mg/cobicistat 150 mg daily, respectively. 70 The greater increases in rosuvastatin exposures with boosted PIs versus elvitegravir/cobicistat may be a result of additional inhibitory effects of atazanavir and darunavir on BCRP and OATP1B1 transporters. 72, 73 Although the elvitegravir/cobicistat monograph states that dose modifications are not required with rosuvastatin, recommendations for cobicistat-boosted PIs are similar to those with ritonavir-boosted PIs plus rosuvastatin-that is, use of the lowest possible dose of rosuvastatin.
Making Switches From a Ritonavir-Boosted Regimen to a Cobicistat-Boosted Regimen
Clinicians and patients may elect to switch from a ritonavirboosted to a cobicistat-boosted regimen or vice versa for a number of reasons. Studies involving switches from ritonavir-to cobicistat-boosted regimens have shown greater treatment satisfaction and minimal differences or improvements in adverse effects. [74] [75] [76] Use of a cobicistat-containing coformulation reduces pill burden and number of prescriptions (an important consideration for patients with out-of-pocket copayments) and ensures that the boosting agent is always dosed at the same time as the accompanying antiretroviral. Conversely, some patients may find a coformulated tablet too large and prefer to take individual agents. In addition, a commercial oral liquid formulation of ritonavir is available for patients who have difficulty swallowing tablets. 2 Generally, when switching from ritonavir to cobicistat, the lack of enzyme-inducing activity with cobicistat should be considered. Concentrations of coadministered drugs that are substrates of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and UGT may increase, and close monitoring with potential dose adjustments are recommended. A recent pharmacokinetic switch study in 12 HIV-infected patients on dolutegravir 50 mg daily plus darunavir 800 mg/ritonavir 100 mg daily illustrates this point. After patients were switched to darunavir 800 mg/cobicistat 150 mg daily with dolutegravir, darunavir exposures remained stable, but dolutegravir C trough increased by 100%. The authors hypothesized that dolutegravir exposures may have decreased secondary to ritonavir induction of glucuronidation; switching to cobicistat removed the UGT induction effect, resulting in increased dolutegravir concentrations. 77 Similarly, when switching from a cobicistat-to a ritonavir-boosted regimen, exposures of comedications that are substrates of these enzymes may decrease, and dose increases may be required to maintain therapeutic effect. The onset and dissolution of enzyme-inducing activity may take 1 to 2 weeks, and appropriate clinical monitoring and potential dose adjustments should be planned within this time frame.
Consideration should also be given to the pharmacological characteristics of the agent being boosted as well as the booster as highlighted by interactions with warfarin. As previously discussed, cobicistat lacks induction properties, and increased INR was observed following a switch from a ritonavir-boosted PI to a cobicistat-boosted PI in a patient on stable warfarin. 57 However, if a patient on a ritonavirboosted PI was changed to elvitegravir/cobicistat, then a noticeable change in INR may not occur because elvitegravir itself induces CYP2C9. 55 Other interaction combinations, such as those involving gastric-acid reducing agents, oral contraceptives, or buprenorphine, serve as examples where important pharmacological differences between individual antiretrovirals and specific boosting agents can be associated with different interaction outcomes.
Summary
Cobicistat and ritonavir are generally considered equivalent pharmacokinetic boosters, with similar inhibitory effects on CYP3A4, CYP2D6, P-gp, and other transporters. Similar exposures of elvitegravir, atazanavir, and darunavir are achieved when combined with either booster. In the presence of inducers such as rifamycins or anticonvulsants, cobicistat may not be as effective as ritonavir in terms of inhibiting CYP3A4. Pharmacokinetic drug interaction data for cobicistat are often extrapolated from ritonavir-boosted antiretrovirals; however, this approach may not be appropriate because cobicistat is not associated with enzyme-inducing properties.
Significant problems can arise when switching from a ritonavir-boosted regimen to a cobicistat-boosted regimen or vice versa in patients stabilized on a dose of a relevant substrate agent. Clinicians should be aware of these important differences and distinctions when assessing and managing potential drug interactions with ritonavir or cobicistat-based regimens, particularly in patients with multiple comorbidities and concomitant medications. Depending on the comedications used, additional monitoring and/or dose adjustments may be required. Because new interaction data are continually emerging, clinicians are encouraged to utilize HIVspecific drug interaction resources, such as http://www. hiv-druginteractions.org or http://app.hivclinic.ca, for up-todate information.
